NASDAQ: OCX - OncoCyte Corporation

Rentabilité sur six mois: +2.76%
Secteur: Healthcare

Calendrier des promotions OncoCyte Corporation

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.

Plus de détails
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Выручка 1.6E-5
EBITDA -0.0217
Число акций ао 0.1108 млрд
P/S 7726.46
P/BV 18.24
EV/EBITDA -4.96
Цена ао 3
ISIN US68235C1071
Сайт https://oncocyte.com
Валюта usd
IPO date 2016-01-04
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Changement de prix par jour: -2.3% (3.05)
Changement de prix par semaine: +0.3367% (2.97)
Changement de prix par mois: -6.58% (3.19)
Changement de prix sur 3 mois: -1.65% (3.03)
Changement de prix sur six mois: +2.76% (2.9)
Changement de prix par an: -5.4% (3.15)
Evolution du prix sur 3 ans: -25.5% (4)
Evolution du prix sur 5 ans: +49.75% (1.99)
Evolution des prix depuis le début de l'année: +7.19% (2.78)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 13.18 1
P/BV 0.7742 9
P/E 0 0
EV/EBITDA -0.6515 0
Total: 4.88

Efficacité

Nom Signification Grade
ROA, % -37.09 0
ROE, % -108.54 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.141 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 9293.75 10
Rentabilité Ebitda, % -6.25 0
Rentabilité EPS, % -58.31 0
Total: 3.4
Plus de détails

Établissements Volume Partager, %
Broadwood Capital, Inc. 2509066 30.37
AWM Investment Company, Inc. 754286 9.13
PURA VIDA INVESTMENTS, LLC 586930 7.11
Vanguard Group Inc 247873 3
Morgan Stanley 122973 1.49
Defender Capital, LLC 71650 0.87
Geode Capital Management, LLC 61482 0.74
Blackrock Inc. 60187 0.73
State Street Corporation 16289 0.2
Renaissance Technologies, LLC 12718 0.15

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares Micro-Cap ETF 0.00668 34.327031588619 1.54048



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Joshua Riggs President, CEO & Director 504.63k 1983 (41 année)
Mr. James Liu Senior Director, Controller & Principal Accounting Officer 259.83k 1996 (28 années)
Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer 409.27k
Mr. Yuh-Min Chiang Ph.D. Chief Technology Officer N/A
Dr. Michael D. West Ph.D. Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. N/A 1953 (71 année)
Mr. Peter Hong VP, General Counsel & Secretary N/A
Ms. Andrea Susan James Chief Financial Officer
Ms. Sandra O'Donald Senior Vice President of Business Operations

Adresse: United States, Irvine. CA, 15 Cushing - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://oncocyte.com